Clario expands oncology trial support through collaboration with Radialogica to enhance radiation therapy quality control
- Solutions provide sponsors greater control and consistency when radiation therapy is part of the clinical trial protocol.
PHILADELPHIA, PA – September 23, 2025 – Clario, a leading provider of endpoint data solutions to the clinical trials industry, has expanded its oncology trial support by collaborating with Radialogica to offer enhanced quality control for radiation therapy (RT). This new capability helps sponsors ensure radiation is delivered consistently and according to protocol across global sites, improving trial integrity and the reliability of safety and efficacy outcomes.
As radiation therapy continues to play an important role in modern oncology trials, sponsors are increasingly looking for ways to reduce variability and strengthen oversight. Through this collaboration, Clario now offers centralized, expert-led review of RT plans and treatment delivery, covering both past and ongoing radiotherapy, to support oncology studies through its comprehensive imaging services.
“With radiation therapy, small inconsistencies can create major impacts on trial outcomes,” said Anu Bansal, M.D., Vice President, Imaging, Oncology at Clario. “By integrating radiation QA into our offering, we’re giving sponsors more confidence in their data and more control over how protocol-driven care is delivered across sites.”
Since 1972, Clario’s endpoint data solutions have supported more than 30,000 clinical trial opportunities, including 5,000+ in oncology, at every phase of drug development with regulatory-grade evidence, advanced imaging science, and operational excellence. The addition of radiation QA further strengthens Clario’s ability to help sponsors navigate complex protocols involving multiple treatment modalities.
Radialogica brings experience in radiation oncology and a proven track record of delivering independent, centralized quality review in both clinical and trial settings. Their services are now available as part of Clario’s oncology imaging solutions, offering sponsors a single, expert-led partner for all trial imaging and RT oversight needs.
“We’re proud to be working with Clario to help sponsors achieve greater standardization and confidence in radiation delivery,” said Andrew C. Cowen, Chief Executive Officer at Radialogica. “This collaboration aligns with our shared mission of supporting high-quality, patient-focused cancer research.”
This offering was developed in response to increasing sponsor requests for centralized RT quality control and reflects Clario’s commitment to evolving alongside sponsor needs, while continuing to ensure scientific and operational rigor.
About Clario
Clario is a leading provider of endpoint data solutions to the clinical trials industry, generating high-quality clinical evidence for our pharmaceutical, biotech, and medical device partners. We offer comprehensive evidence generation solutions that combine eCOA, cardiac solutions, medical imaging, precision motion, and respiratory endpoints.
For more than 50 years, Clario has delivered deep scientific expertise and broad endpoint technologies to help transform lives around the world. Our endpoint data solutions have supported over 30,000 clinical trial opportunities in more than 100 countries. Our global team of science, technology, and operational experts have supported over 70% of all FDA drug approvals since 2015.
For more information, go to Clario.com or follow us on LinkedIn.
About Radialogica
Radialogica specializes in quality assurance for radiation oncology, offering centralized review of treatment planning and delivery to improve safety, consistency, and adherence to protocol. Their services are used in both clinical practice and clinical trials worldwide.